PRA Health Sciences Stock Price, News & Analysis (NASDAQ:PRAH)

PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."

PRA Health Sciences Inc (NASDAQ:PRAH) released its quarterly earnings results on Wednesday, July, 31st. The medical research company reported $1.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.11 by $0.11. The medical research company earned $763.31 million during the quarter, compared to the consensus estimate of $764.95 million. PRA Health Sciences had a return on equity of 26.64% and a net margin of 5.39%. The business's revenue was up 5.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.00 EPS. View PRA Health Sciences' Earnings History.

PRA Health Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, October 30th 2019. View Earnings Estimates for PRA Health Sciences.

PRA Health Sciences will be holding an earnings conference call on Wednesday, October 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

PRA Health Sciences issued an update on its FY 2019 earnings guidance on Wednesday, July, 31st. The company provided EPS guidance of $4.98-5.08 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.01. The company issued revenue guidance of $3.02-3.1 billion, compared to the consensus revenue estimate of $3.1 billion.

9 equities research analysts have issued twelve-month price targets for PRA Health Sciences' shares. Their predictions range from $100.00 to $126.00. On average, they anticipate PRA Health Sciences' stock price to reach $115.86 in the next year. This suggests a possible upside of 19.8% from the stock's current price. View Analyst Price Targets for PRA Health Sciences.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PRA Health Sciences in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PRA Health Sciences.

Press coverage about PRAH stock has trended somewhat positive this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. PRA Health Sciences earned a daily sentiment score of 0.8 on InfoTrie's scale. They also assigned headlines about the medical research company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for PRA Health Sciences.

Some companies that are related to PRA Health Sciences include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), Exelixis (EXEL), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Intrexon (XON), Auxly Cannabis Group (CBWTF), STARPHARMA HOLD/S (SPHRY), Sorrento Therapeutics (SRNE), Luna Innovations (LUNA) and Pieris Pharmaceuticals (PIRS).

Based on aggregate information from My MarketBeat watchlists, some companies that other PRA Health Sciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Adobe (ADBE), Applied Materials (AMAT), Paypal (PYPL), Lam Research (LRCX), Veeva Systems (VEEV), Netflix (NFLX), Splunk (SPLK) and GrubHub (GRUB).

(PRAH) raised $306 million in an initial public offering (IPO) on Thursday, November 13th 2014. The company issued 17,000,000 shares at $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

PRA Health Sciences' stock is owned by many different of retail and institutional investors. Top institutional investors include Stephens Investment Management Group LLC (0.69%), Artemis Investment Management LLP (0.36%), CIBC Private Wealth Group LLC (0.26%), Scout Investments Inc. (0.14%), Reilly Financial Advisors LLC (0.13%) and Pacer Advisors Inc. (0.03%). Company insiders that own PRA Health Sciences stock include David W Dockhorn, Fund Holdings LP Kkr, Linda Baddour, Matthew P Young and Pra Investors LP Kkr. View Institutional Ownership Trends for PRA Health Sciences.

PRAH stock was sold by a variety of institutional investors in the last quarter, including Bowling Portfolio Management LLC, Scout Investments Inc., Campbell & CO Investment Adviser LLC, Pacer Advisors Inc., CIBC Private Wealth Group LLC and Nisa Investment Advisors LLC. View Insider Buying and Selling for PRA Health Sciences.

PRAH stock was acquired by a variety of institutional investors in the last quarter, including Reilly Financial Advisors LLC, Artemis Investment Management LLP, Stephens Investment Management Group LLC, Fox Run Management L.L.C., State of Alaska Department of Revenue, Brinker Capital Inc., Toth Financial Advisory Corp and Envestnet Asset Management Inc.. View Insider Buying and Selling for PRA Health Sciences.

Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PRAH stock can currently be purchased for approximately $96.71.

PRA Health Sciences has a market capitalization of $6.37 billion and generates $2.87 billion in revenue each year. The medical research company earns $153.90 million in net income (profit) each year or $3.93 on an earnings per share basis. PRA Health Sciences employs 16,400 workers across the globe.View Additional Information About PRA Health Sciences.

The official website for PRA Health Sciences is http://www.prahs.com/.

PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected]